NCT07906418|Not Yet Recruiting
BCMA Polymorphisms in Patients With Multiple Myeloma
BCMA in MM
The Effect of B Cell Maturation Antigen (BCMA) Polymorphisms on Treatment Response and Survival in Patients With Multiple Myeloma
Loading search results
BCMA in MM
The Effect of B Cell Maturation Antigen (BCMA) Polymorphisms on Treatment Response and Survival in Patients With Multiple Myeloma
Sponsor study identifier
Secondary identifiers
OTHER_GRANT · Johnson & Johnson Innovative Medicine
observational
420
1 country
1
Study Start
November 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
December 15, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
February 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The aim of this study is to investigate the effect of B cell maturation antigen (BCMA, TNFRSF17) gene polymorphisms on treatment response and survival in patients with multiple myeloma. BCMA is a member of the tumor necrosis factor receptor superfamily that is expressed on late memory B cells and all plasma cells. Together with the B cell activating factor receptor (BAFF-R) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI), BCMA binds the ligands B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), thereby regulating the survival, maturation, and differentiation of B cells and plasma cells. In this study, BCMA polymorphisms will be analyzed by next-generation sequencing in stored genomic DNA samples from 320 patients with multiple myeloma and 100 healthy controls. Genotype frequencies will be compared between patients and controls, and their association with response to first-line treatment, progression-free survival, and overall survival will be evaluated in patients with multiple myeloma.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 15, 2026
Actual (reported)October 30, 2026
Actual (reported)November 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 15, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
February 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Percentage of patients achieving partial response or better after first-line induction therapy, by BCMA genotype
Treatment response will be assessed according to the International Myeloma Working Group (IMWG) 2016 response criteria. Patients achieving complete response, very good partial response, or partial response will be classified as responders, and those with stable or progressive disease as non-responders. The percentage of responders will be compared across BCMA (TNFRSF17) genotypes determined by next-generation sequencing.
After 4 cycles of induction therapy (approximately 16 weeks from the start of treatment)
Progression-free survival (PFS) by BCMA genotype
From diagnosis to disease progression or death, assessed up to 144 months
Overall survival (OS) by BCMA genotype
From diagnosis to death from any cause, assessed up to 144 months
Frequency of BCMA genotypes in patients with multiple myeloma and healthy controls
At enrollment (single genotyping assessment)
Patients with newly diagnosed multiple myeloma who received first-line induction therapy and have stored genomic DNA samples and clinical follow-up data
Healthy individuals without hematological disease, malignancy, or chronic inflammatory or autoimmune disease
Genetic: BCMA polymorphism analysis
Patients with diagnosed multiple myeloma who were treated at Başakşehir Çam and Sakura City Hospital and have stored genomic DNA samples and clinical follow-up data, and healthy controls without hematological disease, malignancy, or chronic inflammatory disease.
Istanbul Basaksehir Cam and Sakura City Hospital
Istanbul, Turkey (Türkiye)
Genomic DNA isolated from peripheral blood leukocytes of patients and healthy controls, stored at -20°C
First Submitted
October 15, 2026
First Posted
October 30, 2026
Study Start
November 1, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
December 15, 2026
EstimatedA Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
February 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 30, 2026
Record last verified: 2026-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: